M. Arumi de Dios

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

A. Prat, P. Villagrasa, B. González-Farré, 2021, Frontiers in Oncology.

202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer

B. González-Farré, T. Pascual, J. Guerra, 2022, Annals of Oncology.

124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial

A. Prat, J. M. Ferrero-Cafiero, T. Pascual, 2023, ESMO Open.